Haematologica

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recommendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

The trajectory of measurable residual disease (MRD) recurrence in acute myeloid leukemia patients who achieved MRD-negat...
22/12/2025

The trajectory of measurable residual disease (MRD) recurrence in acute myeloid leukemia patients who achieved MRD-negative remission following induction chemotherapy: a new study analyzes a cohort of 767 patients who had achieved MRD-negative remission within two cycles of induction therapy, suggesting modifications to the ELN-recommended MRD threshold of ≥0.1%, and supporting the redefinition of MRD positivity to any detectable level.
https://haematologica.org/article/view/12103

“Time and space are not conditions of existence, time and space are models for thinking.” Albert Einstein. We can probab...
18/12/2025

“Time and space are not conditions of existence, time and space are models for thinking.” Albert Einstein. We can probably draw an analogy with the dimension of “where” to capture measurable residual disease (MRD) and “when” (timepoint) to check it in acute myeloid leukemia, asking whether different methods and observers perceive these in the same way.
In this issue of Haematologica, Ngai and colleagues describe the prognostic value, with regard to overall survival and incidence of relapse, of different methods of leukemia stem cells quantification across European ELN 2017 risk groups, using data from the HOVON-SAKK132 trial.
https://haematologica.org/article/view/12046

In this issue of Haematologica, Hogan and colleagues report the outcome of the entire cohort of the COG AALL1331 trial w...
16/12/2025

In this issue of Haematologica, Hogan and colleagues report the outcome of the entire cohort of the COG AALL1331 trial with relapsed acute lymphoblastic leukemia (ALL), making this the largest prospective trial reported on relapsed B-cell precursor ALL.
https://haematologica.org/article/view/12137

Guidelines Article: a consensus panel of global leaders with expertise in managing adult acute lymphoblastic leukemia/ly...
12/12/2025

Guidelines Article: a consensus panel of global leaders with expertise in managing adult acute lymphoblastic leukemia/lymphoma (ALL) review the strategies for mitigating and managing asparaginase (ASNase)-associated toxicities in adult ALL patients, with the intent of optimizing treatment outcomes allowing these patients to receive more or all the planned ASNase doses and thereby improve outcomes.
https://haematologica.org/article/view/11989

Review article on hemophilia: sum up of the best available evidence on novel rebalancing agents, their promising clinica...
10/12/2025

Review article on hemophilia: sum up of the best available evidence on novel rebalancing agents, their promising clinical data and remaining challenges. Highlighting the unknowns, and emphasizing the uncertainties that lie ahead, including the thrombotic risk of rebalancing agents, perioperative and bleeding management, availability in low-income countries, efficacy and factor VIII equivalence compared to existing treatments, ideal target populations, and potential application in other hemostatic disorders.
https://haematologica.org/article/view/12200

Perspective article on phosphoinositide 3-kinase (PI3K) pathway inhibitors: scientific rationale, clinical experience, r...
06/12/2025

Perspective article on phosphoinositide 3-kinase (PI3K) pathway inhibitors: scientific rationale, clinical experience, regulatory hurdles, and future developments of PI3K inhibitors for the treatment of lymphoma and chronic lymphocytic leukemia.
https://haematologica.org/article/view/12191

Landmark paper in hematology: the paper published in The New England Journal of Medicine in 2020, demonstrated a signifi...
04/12/2025

Landmark paper in hematology: the paper published in The New England Journal of
Medicine in 2020, demonstrated a significantly lower venous thromboembolism (VTE) recurrence rate of in the apixaban group versus the dalteparin group, leading to a broad implementation of direct oral anticoagulants in the treatment of cancer-associated VTE.
https://haematologica.org/article/view/13009

Post-transplant cyclophosphamide for acute lymphoblastic leukemia in earlier and later eras: the outcomes of two retrosp...
27/11/2025

Post-transplant cyclophosphamide for acute lymphoblastic leukemia in earlier and later eras: the outcomes of two retrospective cohorts. The importance of effective pre-transplant therapy. A must-read for those following advances in leukemia treatment.
https://haematologica.org/article/view/12054

Non-Langerhans cell histiocytosis comprises a heterogeneous group of diseases including Erdheim-Chester disease, the xan...
25/11/2025

Non-Langerhans cell histiocytosis comprises a heterogeneous group of diseases including Erdheim-Chester disease, the xanthogranuloma family of lesions, Rosai-Dorfman disease, indeterminate cell histiocytosis, and malignant histiocytic neoplasms. In the present review Hershkovitz-Rokah and colleagues synthesize key advancements in the field and propose a blueprint for future research to address unmet needs.
https://haematologica.org/article/view/haematol.2024.286479

The second review on histiocytic disorders regards major clinical and pathobiological milestones in Langerhans cell hist...
23/11/2025

The second review on histiocytic disorders regards major clinical and pathobiological milestones in Langerhans cell histiocytosis (LCH) reached in the last two decades, with a spotlight on critical, unanswered questions that need to be addressed to further improve the clinical management and outcomes of patients with LCH.
https://haematologica.org/article/view/haematol.2024.286478

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by an excessive but ineffe...
21/11/2025

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by an excessive but ineffective immune response leading to cellular hyperactivation and rampant cytokine secretion and can be subdivided into primary HLH and secondary HLH. In their review paper Meyer and colleagues highlight the major biological and clinical advances surrounding HLH in recent decades.
https://haematologica.org/article/view/haematol.2024.286477

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Haematologica:

Scelte rapide

Promuovere

Condividi

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram